At #BIO2024, the Pharmaceutical Industry’s answer to speed dating, EpicentRx declares its relationship status to be “mostly single and totally ready to mingle.” Outside only of oncology in China, where EpicentRx has partnered with SciClone Pharmaceuticals, the company is free to wheel and deal with other potential partners – and this it plans to do in spades.
BIO comes at an opportune time for EpicentRx, which is poised to make a big splash at #ASCO 2024 with an oral presentation on potentially practice-changing results from a Phase 2 clinical trial that features AdAPT-001, the most clinically advanced transforming growth factor beta (TGF-beta) inhibitor.
Also newsworthy for RRx-001 (nibrozetone), the most clinically advanced NLRP3 inflammasome inhibitor in development, are its two ongoing late stage clinical trials, a Phase 3 in small cell lung cancer (SCLC) and a Phase 2b in severe oral mucositis, as well as the 4 prestigious neuroprotective grants that it has been awarded by the Michael J Fox Foundation (MJFF) and the Department of Defense (DoD) in Parkinson’s, by the DoD in toxic central nervous system (CNS) exposures, and by Fight MND for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
2025 is likely to be a breakout year for EpicentRx as interim or top line results from ongoing clinical trials are disclosed, so to any potential partners we meet before then our humble advice is this: better get in now while the getting is good!
Because one thing is for sure: EpicentRx won’t be (mostly) single for much longer.